Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

Home Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

/ Publications

Share the Post

About the Author

Related Posts

Response to Treatment With nab-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECT 
Aadi Bioscience to Participate in Upcoming Investor Conferences
Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)
ABI-009 (nab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase II Registration Trial
Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer
Read More
Stephen Rodin, JD
Biomarker Analysis From AMPECT Correlating Response to nab-Sirolimus in PEComa With TSC1 and TSC2 Inactivating Alterations
Long-Term Follow-Up from AMPECT, an Open-Label Phase 2 Registration Trial of nab-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)

Comments

Comments are closed.